ClinicalTrials.gg
Sign In

Biological

EP4 Receptor Antagonist YY001 clinical trials

Also written YY001.

studies test it
6
open now
2
in phase 3
4
first study started
2022

Keep track of what changes. Save the EP4 Receptor Antagonist YY001 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Name

Rcombinant botulinum neurotoxin type A for injection (YY001)
2
Recombinant botulinum toxin type A for injection (YY001)
2

Development codes

YY001
2

Studies by the year they started

6 studies that test it; most in 2022 (2)

Studies that test EP4 Receptor Antagonist YY001, by start year
YearStudies
20222
20231
20242
20261

By phase

A phase 1/2 study counts in both.

Phase 1
2
Phase 2
2
Phase 3
4

What it is tested for

Each study’s main condition, where its own words name it.

Neoplasms
1

Who runs them

Industry 6 · Other 0

Chongqing Claruvis Pharmaceutical Co., Ltd. (5) · Shanghai Yuyao Biotech Co., Ltd. (1)

Studies

Open first, then newest update. How each study uses EP4 Receptor Antagonist YY001 is read from its arms, and is right about nine times in ten.

Testing it · 6